Published in Pharmacol Rep on January 18, 2010
Zinc homeostasis and neurodegenerative disorders. Front Aging Neurosci (2013) 1.05
Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.89
Zinc deficiency is common in several psychiatric disorders. PLoS One (2013) 0.83
Chronic treatment with zinc and antidepressants induces enhancement of presynaptic/extracellular zinc concentration in the rat prefrontal cortex. Amino Acids (2010) 0.82
Concentration-Dependent Dual Mode of Zn Action at Serotonin 5-HT1A Receptors: In Vitro and In Vivo Studies. Mol Neurobiol (2015) 0.78
Zinc bells rang in Jerusalem! Sci Signal (2010) 0.77
Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. Metab Brain Dis (2016) 0.76
Involvement of glutamatergic neurotransmission in the antidepressant-like effect of zinc in the chronic unpredictable stress model of depression. J Neural Transm (Vienna) (2016) 0.76
Zinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity. Neural Plast (2017) 0.75
The Emerging Role for Zinc in Depression and Psychosis. Front Pharmacol (2017) 0.75
Soil enzyme activities as affected by anthropogenic alterations: intensive agricultural practices and organic pollution. Sci Total Environ (2004) 1.63
Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs (2011) 1.45
Preservation of low frequency hearing in partial deafness cochlear implantation (PDCI) using the round window surgical approach. Acta Otolaryngol (2007) 1.42
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther (2007) 1.41
Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol (2007) 1.22
Preservation of residual hearing in children and post-lingually deafened adults after cochlear implantation: an initial study. ORL J Otorhinolaryngol Relat Spec (2002) 1.18
A new method of partial deafness treatment. Med Sci Monit (2003) 1.16
Hormones and diet, but not body weight, control hypothalamic microglial activity. Glia (2013) 1.15
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci (2013) 1.09
Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol (2004) 1.09
Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety. Eur J Med Chem (2010) 1.07
New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology (2012) 1.06
Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord (2009) 1.05
NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav (2007) 1.01
Partial deafness cochlear implantation provides benefit to a new population of individuals with hearing loss. Acta Otolaryngol (2006) 1.01
Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) (2008) 1.01
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol (2013) 1.00
Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav (2005) 0.99
GABAergic hypotheses of anxiety and depression: focus on GABA-B receptors. Drugs Today (Barc) (2005) 0.99
Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology (2004) 0.99
Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl) (2007) 0.97
Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.97
The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord (2011) 0.96
Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull (2003) 0.96
Outcomes of treatment of partial deafness with cochlear implantation: a DUET study. Laryngoscope (2008) 0.96
The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.96
Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav (2002) 0.95
Antidepressant-like activity of zinc: further behavioral and molecular evidence. J Neural Transm (Vienna) (2008) 0.94
Hearing preservation in partial deafness treatment. Med Sci Monit (2010) 0.94
Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. Eur J Pharmacol (2004) 0.93
mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology (2012) 0.92
(Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.92
Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther (2007) 0.92
Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. J Affect Disord (2010) 0.92
Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep (2008) 0.92
Atraumatic round window deep insertion of cochlear electrodes. Acta Otolaryngol (2011) 0.92
A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. J Neural Transm (Vienna) (2011) 0.91
Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. Neuropharmacology (2010) 0.91
Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int (2009) 0.91
Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors. Eur J Med Chem (2012) 0.90
Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology (Berl) (2002) 0.90
Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology (Berl) (2011) 0.90
Antepartum/postpartum depressive symptoms and serum zinc and magnesium levels. Pharmacol Rep (2006) 0.90
The role of zinc in neurodegenerative inflammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.89
Zinc treatment induces cortical brain-derived neurotrophic factor gene expression. Eur J Pharmacol (2004) 0.89
The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors. J Pharmacol Exp Ther (2006) 0.89
Partial deafness cochlear implantation in children. Int J Pediatr Otorhinolaryngol (2007) 0.89
Direct round window stimulation with the Med-El Vibrant Soundbridge: 5 years of experience using a technique without interposed fascia. Eur Arch Otorhinolaryngol (2013) 0.89
N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: behavioral and biochemical analyses in rats. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.88
Immobility stress induces depression-like behavior in the forced swim test in mice: effect of magnesium and imipramine. Pharmacol Rep (2006) 0.88
On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berl) (2010) 0.88
Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu₄ receptor. Neuropharmacology (2012) 0.88
Zinc and depression. An update. Pharmacol Rep (2005) 0.88
Synthesis, lipophilicity and antimicrobial activity of new derivatives of thiosemicarbazides and 1,2,4-triazoline-5-thione. Acta Pol Pharm (2009) 0.88
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci (2012) 0.87
Results of partial deafness cochlear implantation using various electrode designs. Audiol Neurootol (2009) 0.86
Identification of novel serotonin transporter compounds by virtual screening. J Chem Inf Model (2014) 0.86
Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior. Pharmacol Rep (2008) 0.86
The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling. Psychopharmacology (Berl) (2013) 0.86
Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test. Pharmacol Rep (2012) 0.85
NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice. Pharmacol Rep (2008) 0.85
Interaction of zinc with antidepressants in the forced swimming test in mice. Pol J Pharmacol (2003) 0.85
Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav (2004) 0.85
Human Freud-2/CC2D1B: a novel repressor of postsynaptic serotonin-1A receptor expression. Biol Psychiatry (2009) 0.85
Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity. Eur J Med Chem (2009) 0.85